Cargando…
CRISPR-Cas systems: ushering in the new genome editing era
In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067892/ https://www.ncbi.nlm.nih.gov/pubmed/29968520 http://dx.doi.org/10.1080/21655979.2018.1470720 |
_version_ | 1783343186131812352 |
---|---|
author | Perez Rojo, Fernando Nyman, Rikard Karl Martin Johnson, Alexander Arthur Theodore Navarro, Maria Pazos Ryan, Megan Helen Erskine, William Kaur, Parwinder |
author_facet | Perez Rojo, Fernando Nyman, Rikard Karl Martin Johnson, Alexander Arthur Theodore Navarro, Maria Pazos Ryan, Megan Helen Erskine, William Kaur, Parwinder |
author_sort | Perez Rojo, Fernando |
collection | PubMed |
description | In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided. |
format | Online Article Text |
id | pubmed-6067892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-60678922019-07-03 CRISPR-Cas systems: ushering in the new genome editing era Perez Rojo, Fernando Nyman, Rikard Karl Martin Johnson, Alexander Arthur Theodore Navarro, Maria Pazos Ryan, Megan Helen Erskine, William Kaur, Parwinder Bioengineered Commentary In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided. Taylor & Francis 2018-07-03 /pmc/articles/PMC6067892/ /pubmed/29968520 http://dx.doi.org/10.1080/21655979.2018.1470720 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Perez Rojo, Fernando Nyman, Rikard Karl Martin Johnson, Alexander Arthur Theodore Navarro, Maria Pazos Ryan, Megan Helen Erskine, William Kaur, Parwinder CRISPR-Cas systems: ushering in the new genome editing era |
title | CRISPR-Cas systems: ushering in the new genome editing era |
title_full | CRISPR-Cas systems: ushering in the new genome editing era |
title_fullStr | CRISPR-Cas systems: ushering in the new genome editing era |
title_full_unstemmed | CRISPR-Cas systems: ushering in the new genome editing era |
title_short | CRISPR-Cas systems: ushering in the new genome editing era |
title_sort | crispr-cas systems: ushering in the new genome editing era |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067892/ https://www.ncbi.nlm.nih.gov/pubmed/29968520 http://dx.doi.org/10.1080/21655979.2018.1470720 |
work_keys_str_mv | AT perezrojofernando crisprcassystemsusheringinthenewgenomeeditingera AT nymanrikardkarlmartin crisprcassystemsusheringinthenewgenomeeditingera AT johnsonalexanderarthurtheodore crisprcassystemsusheringinthenewgenomeeditingera AT navarromariapazos crisprcassystemsusheringinthenewgenomeeditingera AT ryanmeganhelen crisprcassystemsusheringinthenewgenomeeditingera AT erskinewilliam crisprcassystemsusheringinthenewgenomeeditingera AT kaurparwinder crisprcassystemsusheringinthenewgenomeeditingera |